Immunogenomic and ageing determinants of therapy response in brain metastasis

Brain metastases are a common and often fatal consequence of primary cancer. Although immunotherapies hold promise, a large fraction of patients remains unresponsive, likely due to the heterogeneity of their tumour immune microenvironment. Immune responses can be affected by genetics and ageing, but their interplay remains poorly understood. The ERC-funded IMMUNAGENOMICS project explores the impact of these factors on anti-tumoural immunity and therapy outcomes by combining novel methods such as single-cell sequencing, spatial transcriptomics and imaging. Project work could provide the basis for individually tailored, improved therapies for treating brain metastatic cancer